Avicanna 관리

관리 기준 확인 2/4

Avicanna CEO는 Aras Azadian, Jan2016 에 임명되었습니다 의 임기는 8.83 년입니다. 총 연간 보상은 CA$ 336.01K, 26.3% 로 구성됩니다. 26.3% 급여 및 73.7% 보너스(회사 주식 및 옵션 포함). 는 CA$ 1.03M 가치에 해당하는 회사 주식의 4.11% 직접 소유합니다. 1.03M. 경영진과 이사회의 평균 재임 기간은 각각 1.9 년과 3.4 년입니다.

주요 정보

Aras Azadian

최고 경영자

CA$336.0k

총 보상

CEO 급여 비율	26.3%
CEO 임기	8.8yrs
CEO 소유권	4.1%
경영진 평균 재임 기간	1.9yrs
이사회 평균 재임 기간	3.4yrs

최근 관리 업데이트

Recent updates

Take Care Before Jumping Onto Avicanna Inc. (TSE:AVCN) Even Though It's 31% Cheaper

Nov 17

Why Investors Shouldn't Be Surprised By Avicanna Inc.'s (TSE:AVCN) 35% Share Price Surge

Aug 28

Market Participants Recognise Avicanna Inc.'s (TSE:AVCN) Revenues Pushing Shares 79% Higher

Jul 11

CEO 보상 분석

Aras Azadian 의 보수는 Avicanna 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-CA$7m
Jun 30 2024	n/a	n/a	-CA$7m
Mar 31 2024	n/a	n/a	-CA$7m
Dec 31 2023	CA$336k	CA$88k	-CA$9m
Sep 30 2023	n/a	n/a	-CA$12m
Jun 30 2023	n/a	n/a	-CA$14m
Mar 31 2023	n/a	n/a	-CA$16m
Dec 31 2022	CA$486k	CA$161k	-CA$15m
Sep 30 2022	n/a	n/a	-CA$16m
Jun 30 2022	n/a	n/a	-CA$16m
Mar 31 2022	n/a	n/a	-CA$15m
Dec 31 2021	CA$244k	CA$127k	-CA$17m
Sep 30 2021	n/a	n/a	-CA$24m
Jun 30 2021	n/a	n/a	-CA$29m
Mar 31 2021	n/a	n/a	-CA$34m
Dec 31 2020	CA$358k	CA$110k	-CA$33m
Sep 30 2020	n/a	n/a	-CA$25m
Jun 30 2020	n/a	n/a	-CA$24m
Mar 31 2020	n/a	n/a	-CA$21m
Dec 31 2019	CA$608k	CA$240k	-CA$22m
Sep 30 2019	n/a	n/a	-CA$18m
Jun 30 2019	n/a	n/a	-CA$14m
Mar 31 2019	n/a	n/a	-CA$11m
Dec 31 2018	CA$150k	CA$150k	-CA$7m
Sep 30 2018	n/a	n/a	-CA$5m
Dec 31 2017	CA$180k	CA$150k	-CA$3m

보상 대 시장: Aras 의 총 보상 ($USD 238.49K )은 Canadian 시장( $USD 170.34K ).

보상과 수익: Aras 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Aras Azadian

8.8yrs

테뉴어

CA$336,008

보상

Mr. Aras Azadian, M. Mgmt, Msc Management, B.Econ, MBA, is a Co-Founder of Avicanna Inc. He serves as Chief Executive Officer and Director since November 25, 2016 of Avicanna Inc. and served as its Chairma...

리더십 팀

이름	위치	테뉴어	보상	소유권
Aras Azadian	Co-Founder	8.8yrs	CA$336.01k	4.11% CA$ 1.0m
Phillip Cardella	Chief Financial Officer	1.9yrs	CA$254.02k	0.64% CA$ 161.3k
Ivana Maric	Executive Vice President of Marketing	no data	CA$249.08k	데이터 없음
Stephen Kim	Chief Legal Officer & General Counsel of Avicanna USA Inc.	1.9yrs	CA$396.48k	데이터 없음
Karolina Urban	Executive Vice President of Scientific & Medical Affairs	1.4yrs	CA$255.87k	데이터 없음
Arash Moghani	Executive Vice President of Operations & Technology	no data	데이터 없음	데이터 없음
Ingrid Diaz	VP, Assistant General Counsel & Corporate Compliance Officer	1.4yrs	데이터 없음	데이터 없음
Enric Pujol	Vice President of People	no data	데이터 없음	데이터 없음
Carlos Enrique Muete	SVP of Clinical Development	no data	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

경험이 풍부한 관리: AVCN 의 관리팀은 경험 (평균 재직 기간 1.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Aras Azadian	Co-Founder	8yrs	CA$336.01k	4.11% CA$ 1.0m
Sheldon Inwentash	Member of Business Advisory Board	no data	데이터 없음	5.68% CA$ 1.4m
Paul Fornazzari	Independent Director	less than a year	CA$12.31k	0.94% CA$ 235.0k
Daniel Sauder	Member of Global Scientific Advisory Board	no data	데이터 없음	데이터 없음
Giancarlo Char	Director	6.1yrs	CA$88.30k	0.65% CA$ 162.7k
Aline Masuda	Member of Business Advisory Board	no data	데이터 없음	데이터 없음
Mauricio Torres-Pradilla	Member of Global Scientific Advisory Board	no data	데이터 없음	데이터 없음
Humberto Reynales	Member of International Scientific Advisory Board	no data	데이터 없음	데이터 없음
Max Jones	Member of Global Scientific Advisory Board	no data	데이터 없음	데이터 없음
John McVicar	Independent Director	3.4yrs	CA$118.75k	0.46% CA$ 115.0k
Eileen McCormack	Independent Director	2.8yrs	CA$110.18k	0.26% CA$ 64.3k
Al Harrington	Member of Business Advisory Board	no data	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: AVCN 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

Avicanna 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Member of Business Advisory Board recently bought CA$60k worth of stock

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought CA$251k worth of stock

Less than half of directors are independent

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Recent updates

Take Care Before Jumping Onto Avicanna Inc. (TSE:AVCN) Even Though It's 31% Cheaper

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna Inc. announced that it has received CAD 0.80001 million in funding

Avicanna Inc. announced that it has received CAD 1.986208 million in funding

Why Investors Shouldn't Be Surprised By Avicanna Inc.'s (TSE:AVCN) 35% Share Price Surge

New major risk - Financial position

Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

New major risk - Share price stability

Market Participants Recognise Avicanna Inc.'s (TSE:AVCN) Revenues Pushing Shares 79% Higher

Member of Business Advisory Board recently bought CA$60k worth of stock

Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought CA$251k worth of stock

It's Down 35% But Avicanna Inc. (TSE:AVCN) Could Be Riskier Than It Looks

First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.033 loss in 1Q 2023)

Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa

Avicanna Inc. announced that it has received CAD 2.125584 million in funding

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study

Shareholders Should Be Pleased With Avicanna Inc.'s (TSE:AVCN) Price

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox

Avicanna Inc. announced that it has received CAD 0.888128 million in funding

Less than half of directors are independent

New major risk - Financial position

Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022)

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023

Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

New minor risk - Share price stability

Second quarter 2023 earnings released: CA$0.021 loss per share (vs CA$0.08 loss in 2Q 2022)

Avicanna Inc. announced that it has received CAD 1.455 million in funding

Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.

New minor risk - Share price stability

Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million.

First quarter 2023 earnings released: CA$0.033 loss per share (vs CA$0.02 loss in 1Q 2022)

Here's Why Avicanna (TSE:AVCN) Can Afford Some Debt

Insider recently bought CA$58k worth of stock

Insider recently bought CA$130k worth of stock

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Avicanna Inc. announced that it has received CAD 1.769097 million in funding

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product

Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Insider recently bought CA$539k worth of stock

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Avicanna Inc. announced that it has received CAD 0.626763 million in funding

Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Assad Kazeminy Retires as Director of Avicanna Inc

Avicanna Inc. announced that it has received CAD 2.782302 million in funding

Second quarter 2022 earnings released: CA$0.08 loss per share (vs CA$0.067 loss in 2Q 2021)

Avicanna Inc., Annual General Meeting, Aug 31, 2022

An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million.

Forecast to breakeven in 2024

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avicanna Inc. Announces Chief Financial Officer Changes

Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc.

Price target decreased to CA$0.70

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Avicanna Inc. announced that it has received CAD 2.523568 million in funding

Avicanna Inc. Provides Consolidated Revenue Guidance for the Fourth Quarter, Full Year 2021 and Full Year 2022

Avicanna Inc. announced that it expects to receive CAD 1.3008 million in funding

CEO 보상 분석

CEO

테뉴어

보상